ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
Turnover
60.53%
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
+12.16%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$188M
AUM Growth
+$22M
(+13%)
Cap. Flow
+$15.2M
Cap. Flow
% of AUM
8.05%
Top 10 Holdings %
Top 10 Hldgs %
64.3%
Holding
38
New
9
Increased
8
Reduced
7
Closed
14
Avg Time Held
0.4
years
Top 10 Avg Time Held
0
years
Top 20 Avg Time Held
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$14.7M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$12.3M |
| 3 |
UnitedHealth
UNH
|
+$12.2M |
| 4 |
IQVIA
IQV
|
+$11.5M |
| 5 |
AbbVie
ABBV
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alkermes
ALKS
|
+$11.5M |
| 2 |
Medtronic
MDT
|
+$10.5M |
| 3 |
Insulet
PODD
|
+$10.4M |
| 4 |
Hologic
HOLX
|
+$10.3M |
| 5 |
Sage Therapeutics
SAGE
|
+$10.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.63% |
| 2 | Financials | 0.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
BioMarin Pharmaceuticals
BMRN
$10.7B
| $15.7M | 8.34% |
+177,741
| New | +$14.7M |
2021 Q4
0 quarters
|
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $14.8M | 7.87% |
137,610
+112,661
| +452% | +$12.3M |
2021 Q3
1 quarter
|
|
|
3
UnitedHealth
UNH
$354B
| $13.5M | 7.16% |
+26,844
| New | +$12.2M |
2021 Q4
0 quarters
|
|
|
4
AbbVie
ABBV
$500B
| $12.8M | 6.79% |
+94,448
| New | +$11.2M |
2021 Q4
0 quarters
|
|
|
5
IQVIA
IQV
$43.2B
| $12.5M | 6.64% |
+44,314
| New | +$11.5M |
2021 Q4
0 quarters
|
|
6
Centene
CNC
$34.5B
| $12.2M | 6.48% |
+148,254
| New | +$10.9M |
2021 Q4
0 quarters
|
|
|
BLU
7
DELISTED
BELLUS Health Inc.
BLU
| $10.3M | 5.47% |
1,280,757
+208,059
| +19% | +$1.38M |
2021 Q3
1 quarter
|
|
8
Cytokinetics
CYTK
$8.84B
| $10.3M | 5.45% |
225,032
-21,304
| -9% | -$822K |
2021 Q3
1 quarter
|
|
9
Johnson & Johnson
JNJ
$610B
| $9.54M | 5.06% |
+55,755
| New | +$9.13M |
2021 Q4
0 quarters
|
|
10
Natera
NTRA
$57.3B
| $9.49M | 5.04% |
+101,674
| New | +$10.6M |
2021 Q4
0 quarters
|
|
11
DELISTED
Amicus Therapeutics
FOLD
| $8.28M | 4.39% |
716,709
+62,733
| +10% | +$699K |
2021 Q2
2 quarters
|
|
12
argenx
ARGX
$51.6B
| $7.31M | 3.88% |
+20,881
| New | +$6.35M |
2021 Q4
0 quarters
|
|
13
Kura Oncology
KURA
$856M
| $7.03M | 3.73% |
502,275
+307,966
| +158% | +$4.99M |
2021 Q3
1 quarter
|
|
14
DELISTED
Apellis Pharmaceuticals
APLS
| $6.59M | 3.5% |
+139,445
| New | +$5.49M |
2021 Q4
0 quarters
|
|
|
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $6.44M | 3.42% |
43,876
+1,885
| +4% | +$293K |
2021 Q1
3 quarters
|
|
|
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $6.29M | 3.34% |
375,989
+20,593
| +6% | +$338K |
2021 Q3
1 quarter
|
|
17
Quanterix
QTRX
$147M
| $6.07M | 3.22% |
143,204
-18,729
| -12% | -$875K |
2021 Q3
1 quarter
|
|
18
DELISTED
iTeos Therapeutics
ITOS
| $4.88M | 2.59% |
104,755
+47,469
| +83% | +$1.58M |
2020 Q3
5 quarters
|
|
19
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $4.69M | 2.49% |
185,201
-89,964
| -33% | -$2.64M |
2021 Q3
1 quarter
|
|
|
AVDL
20
DELISTED
Avadel Pharmaceuticals
AVDL
| $2.98M | 1.58% |
369,134
-105,234
| -22% | -$962K |
2020 Q2
6 quarters
|
|
21
Aclaris Therapeutics
ACRS
$498M
| $2.89M | 1.53% |
198,493
-43,208
| -18% | -$655K |
2021 Q2
2 quarters
|
|
22
PMV Pharmaceuticals
PMVP
$67.4M
| $2.26M | 1.2% |
97,680
-3,202
| -3% | -$77.4K |
2020 Q3
5 quarters
|
|
23
DELISTED
Regulus Therapeutics
RGLS
| $860K | 0.46% |
273,104
+132,955
| +95% | +$591K |
2021 Q1
3 quarters
|
|
|
BLSA
24
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $699K | 0.37% |
71,372
-1,934
| -3% | -$19.1K |
2020 Q4
4 quarters
|
|
|
25
Alkermes
ALKS
$6.57B
| – | – |
-373,382
| Closed | -$11.5M | – |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q4 2021 Portfolio in Review
As of Q4 2021, Asymmetry Capital Management held 38 positions worth $188M, up 13% from $166M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Asymmetry Capital Management deployed $15.2M of net new capital in Q4 2021, opening 9 new positions and adding to 8 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 177,741 shares worth $15.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was DICE Therapeutics, Inc. Common Stock, an estimated $2.64M trimmed.
- Asymmetry Capital Management's largest Q4 2021 buy was BioMarin Pharmaceuticals: 177,741 shares worth $15.7M.
- Asymmetry Capital Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021, an estimated $12.3M increase.
- Asymmetry Capital Management's biggest Q4 2021 reduction was DICE Therapeutics, Inc. Common Stock, cutting an estimated $2.64M.
- Asymmetry Capital Management fully exited Alkermes in Q4 2021, selling an estimated $11.5M.
- Asymmetry Capital Management's ten largest holdings make up 64% of its $188M portfolio in Q4 2021.
- Asymmetry Capital Management opened 9 new positions and closed 14 in Q4 2021.
- Asymmetry Capital Management's portfolio value rose 13% quarter-over-quarter to $188M.
Based on Asymmetry Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.